Spirobenzofuranone compounds

A compound of the formula ##STR19## wherein each of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 is independently hydrogen, C.sub.1-6 alkyl, nitro, halogen, hydroxyl, C.sub.1-6 alkoxy, mono- or di-C.sub.1-4 alkylamino-C.sub.1-6 alkoxy, phenyl-C.sub.1-4 alkyloxy, C.sub.2-6 alkanoyloxy, benzoyloxy, C.sub.2-6 alkanoyl, benzoyl, sulfamoyl, amino, C.sub.1-4 alkylamino, di-C.sub.1-4 alkylamino, C.sub.2-4 alkanoylamino, C.sub.1-4 alkanesulfonylamino, 1-pyrrolidinyl, piperidino, a 1-piperazinyl group, or morpholino, said 1-piperazinyl group being unsubstituted or substituted at the nitrogen atom of its 4-position by C.sub.1-4 alkyl, phenyl-C.sub.1-4 alkyl or C.sub.2-4 alkanoyl, or

• two of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 together form --CH.dbd.CH--CH.dbd.CH-- at adjacent carbon atoms of the benzene ring.

A compound of the formula ##STR20## wherein R.sup.1' is di-C.sub.1-4 alkylamino, or a pharmaceutically acceptable salt thereof.

A compound of the formula ##STR21## wherein R.sup.1" is C.sub.2-6 alkanoyl.

A pharmaceutical composition for managing peptic ulcer which comprises, as an active ingredient, an effective amount of a compound of the formula ##STR23## wherein each of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 independently hydrogen, C.sub.1-6 alkyl, nitro, halogen, hydroxyl, C.sub.1-6 alkoxy, mono- or di-C.sub.1-4 alkylamino-C.sub.1-6 alkoxy, phenyl-C.sub.1-4 alkyloxy, C.sub.2-6 alkanoyloxy, benzoyloxy, C.sub.2-6 alkanoyl, benzoyl, sulfamoyl, amino, C.sub.1-4 alkylamino, di-C.sub.1-4 alkylamino, C.sub.2-4 alkanoylamino, C.sub.1-4 alkanesulfonylamino, 1-pyrrolidinyl, piperidino, a 1-piperazinyl group, or morpholino, said 1-piperazinyl group being unsubstituted or substituted at the nitrogen atom of its 4-position by C.sub.1-4 alkyl, phenyl-C.sub.1-4 alkyl or C.sub.2-4 alkanoyl, or

• two of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 together form --CH.dbd.CH--CH.dbd.CH-- at adjacent carbon atoms of the benzene ring and a pharmaceutically acceptable carrier or diluent therefor.

A method of managing peptic ulcer in a patient which comprises administering to said patient a compound of the formula ##STR25## wherein each of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 is independently hydrogen, C.sub.1-6 alkyl, nitro, halogen, hydroxyl, C.sub.1-6 alkoxy, mono- or di-C.sub.1-4 alkylamino-C.sub.1-6 alkoxy, phenyl-C.sub.1-4 alkyloxy, C.sub.2-6 alkanoyloxy, benzoyloxy, C.sub.2-6 alkanoyl, benzoyl, sulfamoyl, amino, C.sub.1-4 alkylamino, di-C.sub.1-4 alkylamino, C.sub.2-4 alkanoylamino, C.sub.1-4 alkanesulfonylamino, 1-pyrrolidinyl, piperidino, a 1-piperazinyl group, or morpholino, said 1-piperazinyl group being unsubstituted or substituted at the nitrogen atom of its 4-position by C.sub.1-4 alkyl, phenyl-C.sub.1-4 alkyl or C.sub.2-4 alkanoyl, or

• two of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 together form --CH.dbd.CH--CH.dbd.CH-- at adjacent carbon atoms of the benzene ring,
• said compound being administered in an amount effective to manage peptic ulcer in said patient.

A method of managing peptic ulcer in a patient which comprises administering to said patient a compound of the formula ##STR26## wherein R.sup.1' is di-C.sub.1-4 alkylamino, or a pharmaceutically acceptable salt thereof, said compound or salt being administered in an amount effective to manage peptic ulcer in said patient.

A method of managing peptic ulcer in a patient which comprises administering to said patient a compound of the formula ##STR27## wherein R.sup.1" is C.sub.2-6 alkanoyl, said compound being administered in an amount effective to manage peptic ulcer in said patient.